83 related articles for article (PubMed ID: 12902988)
1. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo.
Sharpless NE; Kannan K; Xu J; Bosenberg MW; Chin L
Oncogene; 2003 Aug; 22(32):5055-9. PubMed ID: 12902988
[TBL] [Abstract][Full Text] [Related]
2. Dual Role of the Alternative Reading Frame ARF Protein in Cancer.
Fontana R; Ranieri M; La Mantia G; Vivo M
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30836703
[TBL] [Abstract][Full Text] [Related]
3. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model.
Kannan K; Sharpless NE; Xu J; O'Hagan RC; Bosenberg M; Chin L
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1221-5. PubMed ID: 12538879
[TBL] [Abstract][Full Text] [Related]
4. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo.
Chin L; Pomerantz J; Polsky D; Jacobson M; Cohen C; Cordon-Cardo C; Horner JW; DePinho RA
Genes Dev; 1997 Nov; 11(21):2822-34. PubMed ID: 9353252
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity at the Ink4a/Arf locus facilitates Abelson virus transformation of pre-B cells.
Mostecki J; Halgren A; Radfar A; Sachs Z; Ravitz J; Thome KC; Rosenberg N
J Virol; 2000 Oct; 74(20):9479-87. PubMed ID: 11000217
[TBL] [Abstract][Full Text] [Related]
6. TYMS promotes genomic instability and tumor progression in Ink4a/Arf null background.
Guijarro MV; Nawab A; Dib P; Burkett S; Luo X; Feely M; Nasri E; Seifert RP; Kaye FJ; Zajac-Kaye M
Oncogene; 2023 Jun; 42(23):1926-1939. PubMed ID: 37106126
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.
VanBrocklin MW; Robinson JP; Lastwika KJ; Khoury JD; Holmen SL
Pigment Cell Melanoma Res; 2010 Aug; 23(4):531-41. PubMed ID: 20444198
[TBL] [Abstract][Full Text] [Related]
8. Towards a Better Understanding of the Molecular Mechanisms Involved in Sunlight-Induced Melanoma.
Williams M; Ouhtit A
J Biomed Biotechnol; 2005; 2005(1):57-61. PubMed ID: 15689639
[TBL] [Abstract][Full Text] [Related]
9. Telomerase reactivation induces progression of mouse Braf
Landa I; Thornton CE; Xu B; Haase J; Krishnamoorthy GP; Hao J; Knauf JA; Herbert ZT; Blasco MA; Ghossein R; Fagin JA
bioRxiv; 2023 Jan; ():. PubMed ID: 36747657
[TBL] [Abstract][Full Text] [Related]
10. Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma.
Eddy K; Chen S
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359771
[TBL] [Abstract][Full Text] [Related]
11. Current Molecular Markers of Melanoma and Treatment Targets.
Yang K; Oak ASW; Slominski RM; Brożyna AA; Slominski AT
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429485
[TBL] [Abstract][Full Text] [Related]
12. Genetically engineered mouse models of melanoma.
Pérez-Guijarro E; Day CP; Merlino G; Zaidi MR
Cancer; 2017 Jun; 123(S11):2089-2103. PubMed ID: 28543694
[TBL] [Abstract][Full Text] [Related]
13. Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?
Di Lorenzo S; Fanale D; Corradino B; Caló V; Rinaldi G; Bazan V; Giordano A; Cordova A; Russo A
Cancer Biol Ther; 2016; 17(1):83-90. PubMed ID: 26650572
[TBL] [Abstract][Full Text] [Related]
14. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
[TBL] [Abstract][Full Text] [Related]
15. Circadian clock, cancer, and chemotherapy.
Sancar A; Lindsey-Boltz LA; Gaddameedhi S; Selby CP; Ye R; Chiou YY; Kemp MG; Hu J; Lee JH; Ozturk N
Biochemistry; 2015 Jan; 54(2):110-23. PubMed ID: 25302769
[TBL] [Abstract][Full Text] [Related]
16. Melanoma: from melanocyte to genetic alterations and clinical options.
Bertolotto C
Scientifica (Cairo); 2013; 2013():635203. PubMed ID: 24416617
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a primary and a metastatic melanoma cell line from Grey horses.
Seltenhammer MH; Sundström E; Meisslitzer-Ruppitsch C; Cejka P; Kosiuk J; Neumüller J; Almeder M; Majdic O; Steinberger P; Losert UM; Stöckl J; Andersson L; Sölkner J; Vetterlein M; Golovko A
In Vitro Cell Dev Biol Anim; 2014 Jan; 50(1):56-65. PubMed ID: 23982913
[TBL] [Abstract][Full Text] [Related]
18. Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.
Luo C; Sheng J; Hu MG; Haluska FG; Cui R; Xu Z; Tsichlis PN; Hu GF; Hinds PW
Cancer Res; 2013 Jul; 73(14):4337-48. PubMed ID: 23650282
[TBL] [Abstract][Full Text] [Related]
19. Melanoma: from mutations to medicine.
Tsao H; Chin L; Garraway LA; Fisher DE
Genes Dev; 2012 Jun; 26(11):1131-55. PubMed ID: 22661227
[TBL] [Abstract][Full Text] [Related]
20. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.
Kim M
Small GTPases; 2010 Nov; 1(3):161-164. PubMed ID: 21686270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
